An observational cross-sectional study to determine clinical outcomes in adults with acute migraine using at least 4 doses of ubrogepant in real-world settings

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Apr 2022 Results of a subgroup analysis assessed the real-world effectiveness of ubrogepant for the acute treatment of migraine in patients who switched to ubrogepant due to the lack of efficacy of their prior acute treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022
01 Oct 2021 New trial record
12 Sep 2021 Interim results (n=84) presented at The International Headache Congress - International headache Society with the European headache Federation joint congress 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com